箭头的RNAi药物ARO-INHBE和ARO-ALK7在与替泽帕肽联合使用时，在肥胖患者中表现出显著的早期减重和减脂效果，且无严重安全性问题。 Arrowhead's RNAi drugs ARO-INHBE and ARO-ALK7 showed strong early weight loss and fat reduction in obese patients when combined with tirzepatide, with no serious safety issues.

ARO-INHBE和ARO-ALK7两个治疗肥胖症的RNAi治疗方案ARO-INHBE和ARO-ALK7进行了第1/2阶段的试验,结果令人乐观。 Arrowhead Pharmaceuticals reported promising early results from Phase 1/2a trials of two RNAi therapies, ARO-INHBE and ARO-ALK7, for treating obesity. 与单独使用tirzepatide相比,ARO- INHBE与tirezepatide联合使用导致体重减轻近两倍,内脏脂肪,总脂肪和肝脂肪减少三倍,患者体重减轻高达9. 4%,肝脂肪减少77% When combined with tirzepatide, ARO-INHBE led to nearly double the weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone, with up to 9.4% weight loss and 77% liver fat reduction in patients with type 2 diabetes. ARO-INHBE还显著降低了活性E水平和增加了瘦组织。 ARO-INHBE also significantly lowered Activin E levels and increased lean tissue. ARO-ALK7显示依赖剂量的基因静默,内脏脂肪减少了14.1%。 ARO-ALK7 showed dose-dependent gene silencing and a 14.1% reduction in visceral fat. 这两种疗法都是在没有严重的安全顾虑的情况下得到良好治疗的。 Both therapies were well-tolerated with no serious safety concerns. 成果是初步的,预计2026年会有额外数据。 Results are preliminary, and additional data are expected in 2026.